Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin and enzalutamide in castration resistant prostate cancer (IMPROVE)
NCT02640534Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2016
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of metformin in prostate cancer (PCa), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2016; status: terminated.
02
Drugs
metformin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02640534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640534.